{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:33:18Z","timestamp":1774355598271,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["P500PB_222313"],"award-info":[{"award-number":["P500PB_222313"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WELLCOTR\/WT_PHD_PROGRAMME 218518\/Z\/19\/Z"],"award-info":[{"award-number":["WELLCOTR\/WT_PHD_PROGRAMME 218518\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["UKRI EP\/X027082\/1"],"award-info":[{"award-number":["UKRI EP\/X027082\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Health","award":["1R01AI179771 - 01A1"],"award-info":[{"award-number":["1R01AI179771 - 01A1"]}]},{"DOI":"10.13039\/501100000360","name":"Scottish Funding Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000360","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HORIZON EUROPE European Research Council (ERC) Consolidator Grant","award":["101045464"],"award-info":[{"award-number":["101045464"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Praziquantel is the drug of choice for parasitic diseases such as opisthorchiasis, schistosomiasis, and taeniasis. The U.S. Food and Drug Administration and World Health Organization (WHO) advise administering praziquantel with food to increase absorption and decrease side effects. However, there is a scarcity of evidence on the impact of food, and different types of food, on treatment outcomes. This review aims to address this knowledge gap by (i) examining how pre-treatment food intake is reported in humans, and characterising the types of food provided, if any, and (ii) assessing whether the presence and\/or type of food impacts four key treatment outcomes in humans: absorption, metabolism, treatment-associated side effects, and drug efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We will search the following databases: Embase (via Ovid), MEDLINE (via PubMed), Web of Science Core Collection, Cochrane Central Register of Controlled Trials (CENTRAL), and African Index Medicus (via Global Index Medicus), and trial registries including clinicaltrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP). Additionally, we will perform citation and grey literature searching and will contact researchers to obtain information on ongoing and unpublished relevant research. The search strategy is constructed using two core concepts: (i) praziquantel, and (ii) the outcomes of interest (pharmacokinetics, treatment-associated side effects, and drug efficacy). In Covidence, two review authors will independently screen the retrieved studies based on pre-defined inclusion\/exclusion criteria and extract data using a standardised form. Risk of bias will be assessed using the Risk of Bias 2 (RoB 2) tool for randomised controlled trials and the Risk of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool for non-randomised studies. Data will be synthesised narratively, and random-effects meta-analyses will be conducted to estimate the effect of food on the outcomes of interest, where appropriate. The certainty of evidence will be assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This review has the potential to enhance treatment outcomes for individuals and communities living in endemic regions for schistosomiasis and other parasitic diseases treated with praziquantel. Our findings will be of direct relevance for WHO guidelines and, therefore, can help improve the design and impact of future targeted treatment and mass drug administration (MDA) programmes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>PROSPERO CRD420251024296<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13643-026-03082-4","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:54:19Z","timestamp":1771228459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of pre-treatment food on praziquantel absorption, metabolism, treatment-associated side effects, and drug efficacy: a systematic review and meta-analysis protocol"],"prefix":"10.1186","volume":"15","author":[{"given":"Farah","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poppy H. L.","family":"Lamberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2342-0844","authenticated-orcid":false,"given":"Lydia","family":"Trippler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"3082_CR1","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. Geneva: World Health Organization; 2020."},{"key":"3082_CR2","volume-title":"Schistosomiasis and soil-transmitted helminthiases: progress report, 2023","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Schistosomiasis and soil-transmitted helminthiases: progress report, 2023. Geneva: World Health Organization; 2024."},{"issue":"7","key":"3082_CR3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/20477724.2022.2145070","volume":"117","author":"IF Aboagye","year":"2023","unstructured":"Aboagye IF, Addison YAA. Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review. Pathog Glob Health. 2023;117(7):623\u201330. https:\/\/doi.org\/10.1080\/20477724.2022.2145070.","journal-title":"Pathog Glob Health"},{"issue":"1","key":"3082_CR4","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41598-023-28641-w","volume":"13","author":"A Barry","year":"2023","unstructured":"Barry A, Kabatende J, Telele NF, Mnkugwe RH, Mugisha M, Ntirenganya L, et al. Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda. Sci Rep. 2023;13(1):1446. https:\/\/doi.org\/10.1038\/s41598-023-28641-w.","journal-title":"Sci Rep"},{"issue":"4","key":"3082_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/00365540902756505","volume":"41","author":"LM Duus","year":"2009","unstructured":"Duus LM, Christensen AV, Navntoft D, Tarp B, Nielsen HV, Petersen E. The Schistosoma-specific antibody response after treatment in non-immune travellers. Scand J Infect Dis. 2009;41(4):285\u201390. https:\/\/doi.org\/10.1080\/00365540902756505.","journal-title":"Scand J Infect Dis"},{"issue":"12","key":"3082_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.pt.2023.09.006","volume":"39","author":"RM Lim","year":"2023","unstructured":"Lim RM, Arme TM, Pedersen AB, Webster JP, Lamberton PHL. Defining schistosomiasis hotspots based on literature and shareholder interviews. Trends Parasitol. 2023;39(12):1032\u201349. https:\/\/doi.org\/10.1016\/j.pt.2023.09.006.","journal-title":"Trends Parasitol"},{"issue":"4","key":"3082_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1590\/s0074-02762005000400018","volume":"100","author":"IM Silva","year":"2005","unstructured":"Silva IM, Thiengo R, Concei\u00e7\u00e3o MJ, Rey L, Lenzi HL, Pereira Filho E, et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz. 2005;100(4):445\u20139. https:\/\/doi.org\/10.1590\/s0074-02762005000400018.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3082_CR8","doi-asserted-by":"publisher","unstructured":"Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, G\u00e4rtner F, Correia da Costa JM. Praziquantel for schistosomiasis: Single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother. 2017;61(5). https:\/\/doi.org\/10.1128\/aac.02582-16.","DOI":"10.1128\/aac.02582-16"},{"key":"3082_CR9","doi-asserted-by":"publisher","unstructured":"Trippler L, Ali SM, Ali MN, Mohammed UA, Suleiman KR, Ndum NC, et al. Adaptive integrated intervention approaches for schistosomiasis elimination in Pemba: A 4-year intervention study and focus on hotspots. PLoS neglected tropical diseases. 2025;19(5). https:\/\/doi.org\/10.1371\/journal.pntd.0013079.","DOI":"10.1371\/journal.pntd.0013079"},{"issue":"9","key":"3082_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008649","volume":"14","author":"G Zdesenko","year":"2020","unstructured":"Zdesenko G, Mutapi F. Drug metabolism and pharmacokinetics of praziquantel: a review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis. 2020;14(9):e0008649. https:\/\/doi.org\/10.1371\/journal.pntd.0008649.","journal-title":"PLoS Negl Trop Dis"},{"key":"3082_CR11","volume-title":"Biltricide\u00ae tablets (praziquantel)","author":"Food and Drug Administration","year":"2010","unstructured":"Food and Drug Administration. Biltricide\u00ae tablets (praziquantel). U.S. Food and Drug Administration; 2010."},{"issue":"10","key":"3082_CR12","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1128\/aac.44.10.2903-2904.2000","volume":"44","author":"N Castro","year":"2000","unstructured":"Castro N, Medina R, Sotelo J, Jung H. Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother. 2000;44(10):2903\u20134. https:\/\/doi.org\/10.1128\/aac.44.10.2903-2904.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"3082_CR13","volume-title":"The control of schistosomiasis","author":"World Health Organization","year":"1993","unstructured":"World Health Organization. The control of schistosomiasis. Geneva: World Health Organization; 1993."},{"key":"3082_CR14","volume-title":"WHO guideline on control and elimination of human schistosomiasis","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO guideline on control and elimination of human schistosomiasis. Geneva: World Health Organization; 2022."},{"issue":"1","key":"3082_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. https:\/\/doi.org\/10.1186\/2046-4053-4-1.","journal-title":"Syst Rev"},{"key":"3082_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024): Cochrane; 2024. https:\/\/www.cochrane.org\/handbook."},{"key":"3082_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"3","key":"3082_CR18","doi-asserted-by":"publisher","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","volume":"123","author":"WS Richardson","year":"1995","unstructured":"Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12\u20133.","journal-title":"ACP J Club"},{"key":"3082_CR19","unstructured":"Hamdan F. PRISMA flow diagram for article inclusion in the systematic review. BioRender; 2026. https:\/\/BioRender.com\/7ay8u0r."},{"issue":"2","key":"3082_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/hir.12441","volume":"40","author":"S Golder","year":"2023","unstructured":"Golder S, Farrah K, Mierzwinski-Urban M, Barker B, Rama A. Updated generic search filters for finding studies of adverse drug effects in Ovid medline and Embase may retrieve up to 90% of relevant studies. Health Inf Libr J. 2023;40(2):190\u2013200. https:\/\/doi.org\/10.1111\/hir.12441.","journal-title":"Health Inf Libr J"},{"key":"3082_CR21","unstructured":"Veritas Health Innovation. Covidence systematic review software Melbourne, Australia [Available from: https:\/\/www.covidence.org."},{"key":"3082_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"3082_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"1","key":"3082_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/cts.12601","volume":"12","author":"WM Bagchus","year":"2019","unstructured":"Bagchus WM, Bezuidenhout D, Harrison-Moench E, Kourany-Lefoll E, Wolna P, Yalkinoglu O. Relative bioavailability of orally dispersible tablet formulations of levo- and racemic praziquantel: two phase I studies. Clin Transl Sci. 2019;12(1):66\u201376. https:\/\/doi.org\/10.1111\/cts.12601.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"3082_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. Grade guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.026.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"3082_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001640","volume":"11","author":"S Muhumuza","year":"2014","unstructured":"Muhumuza S, Olsen A, Katahoire A, Kiragga AN, Nuwaha F. Effectiveness of a pre-treatment snack on the uptake of mass treatment for schistosomiasis in Uganda: a cluster randomized trial. PLoS Med. 2014;11(5):e1001640. https:\/\/doi.org\/10.1371\/journal.pmed.1001640.","journal-title":"PLoS Med"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03082-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03082-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:48:08Z","timestamp":1774352888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03082-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03082-4","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}